Education
About Us
Working with TipRanks
Follow Us
Algernon Pharmaceuticals (AGNPF)
OTHER OTC:AGNPF
RESEARCH TOOLSreports
Total Valuation
Algernon Pharmaceuticals has a market cap or net worth of $1.58M. The enterprise value is $2.36M.
Market Cap$1.58M
Enterprise Value$2.36M
Share Statistics
Algernon Pharmaceuticals has 27,301,220 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding27,301,220
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Algernon Pharmaceuticals’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -111.23%.
Return on Equity (ROE)-0.23
Return on Assets (ROA)-0.13
Return on Invested Capital (ROIC)-111.23%
Return on Capital Employed (ROCE)-1.11
Revenue Per Employee0.00
Profits Per Employee-502.98K
Employee Count1
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Algernon Pharmaceuticals is -4.19. Algernon Pharmaceuticals’s PEG ratio is 0.04.
PE Ratio-4.19
PS Ratio0.00
PB Ratio0.97
Price to Fair Value0.97
Price to FCF-0.75
Price to Operating Cash Flow-0.78
PEG Ratio0.04
Income Statement
In the last 12 months, Algernon Pharmaceuticals had revenue of 0.00 and earned -502.98K in profits. Earnings per share was -0.03.
Revenue0.00
Gross Profit-26.56K
Operating Income-2.41M
Pretax Income-502.98K
Net Income-502.98K
EBITDA-476.42K
Earnings Per Share (EPS)-0.03
Cash Flow
In the last 12 months, operating cash flow was -2.90M and capital expenditures -84.03K, giving a free cash flow of -2.99M billion.
Operating Cash Flow-2.90M
Free Cash Flow-2.99M
Free Cash Flow per Share-0.11
Dividends & Yields
Algernon Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.16
52-Week Price Change-33.33%
50-Day Moving Average0.06
200-Day Moving Average0.06
Relative Strength Index (RSI)58.67
Average Volume (3m)6.16K
Important Dates
Algernon Pharmaceuticals upcoming earnings date is Jul 25, 2025, TBA Not Confirmed.
Last Earnings DateApr 29, 2025
Next Earnings DateJul 25, 2025
Ex-Dividend Date―
Financial Position
Algernon Pharmaceuticals as a current ratio of 0.42, with Debt / Equity ratio of 0.00%
Current Ratio0.42
Quick Ratio0.42
Debt to Market Cap0.00
Net Debt to EBITDA1.25
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Algernon Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Algernon Pharmaceuticals EV to EBITDA ratio is -3.17, with an EV/FCF ratio of -0.54.
EV to Sales0.00
EV to EBITDA-3.17
EV to Free Cash Flow-0.54
EV to Operating Cash Flow-0.56
Balance Sheet
Algernon Pharmaceuticals has $357.92K in cash and marketable securities with C$0.00 in debt, giving a net cash position of -$357.92K billion.
Cash & Marketable Securities$357.92K
Total DebtC$0.00
Net Cash-$357.92K
Net Cash Per Share-$0.01
Tangible Book Value Per Share-$0.05
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Algernon Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―